Overview

A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump

Status:
RECRUITING

Trial end date:
2026-01-12

Target enrollment:

Participant gender:

Summary

This study looks at the effect and safety of a new fast-acting insulin (NNC0471-0119) in people with type 2 diabetes when given by an insulin pump. The study tests how fast insulin NNC0471-0119 enters bloodstream, how long it stays there and how much it lowers blood sugar. The new insulin NNC0471-0119 will be compared to insulin aspart. The study will last for about 13-67 days (or a half to 2 months).

Phase:

PHASE1

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Insulin Aspart